Heart failure (HF) is a significant contributor to overall mortality in the community and high levels of combined free light chains (cFLC) were associated with increased mortality in the general population. 1, 2 Also cFLC levels have been reported to be associated with unfavourable outcome in chronic kidney disease where cardiovascular disease was the major cause of death; CKD is common finding in patients with HF. 3 In the present study, we tested the hypothesis that cFLC levels are abnormal in HF, with the greatest abnormalities seen in acute decompensated HF. Second, we hypothesised that cFLC levels would have prognostic implications for 'death and HF hospitalisation'
Methods
Forty nine consecutive patients admitted to hospital with acute HF (AHF group) of ischemic etiology were recruited and compared to 37 patients with stable chronic HF (SHF group), 43 patients with stable coronary artery disease free from HF (CAD group, 'disease controls'), and 37 healthy controls (HC group). AHF was defined in accordance with the European Society of Cardiology guidelines as the rapid onset/progression of HF symptoms and signs related to reduced cardiac contractility requiring hospital admission (New York Heart Association (NYHA) class symptoms). 4 The SHF group included patients with LVEF ≤40% and no deterioration in clinical condition, hospital admission or change in medication for the preceding six months. All SHF patients had an ischaemic etiology of HF. In this group, 10 (27%) patients had NYHA I class symptoms, 24 (65%) patients had NYHA II class symptoms, and 3 (8%) had NYHA III class symptoms. For CAD 'disease control' group eligibility, criteria included history of myocardial infarction >6 months previously and/or angiographically documented stenosis >50% in ≥1 coronary artery and LVEF >50%. Patients with SHF and CAD were recruited from outpatient clinics at Sandwell and West Birmingham Hospitals NHS Trust. The study was performed in accordance with the Helsinki declaration and was approved by the Warwickshire Research Ethics Committee. All participants provided written informed consent.
To minimise potential confounders, CAD was the aetiology of HF in all patients. This inclusion criterion enabled both AHF and SHF patients to be compared to the CAD group as disease controls with a similar profile of cardiovascular risk factors and co-morbidities (e.g. diabetes, hypertension) and medications used. For all study groups, exclusion criteria included infectious and inflammatory disorders, cancer, haemodynamically significant valvular heart disease, creatinine >200 µmol/l), steroids and hormone replacement therapy. BNP was measured using a commercially available enzyme immunoassay set (human BNP-32, Peninsula Laboratories, LLC, CA, USA) according to manufacturer's specifications. 7, 8 The inter-and intra-assay coefficients of variation for interleukin-6 and BNP assays were
Normally distributed data are presented as mean ± standard deviation (SD) and nonnormally distributed data are shown as median (interquartile range, IQR). Cross-sectional comparisons between the four study populations were made using a chi-square test (for categorical variables), one way analysis of variance (ANOVA) with Tukey post-hoc test (for normal data) or Kruskal-Wallis test with Dunn's post-hoc test (for non-normal data).
Longitudinal analysis was performed using repeated measures ANOVA with Bonferroni adjustment (normal data) or Friedman test with Dunn's post-hoc test (non-normal data). Only AHF patients who completed 3 months follow-up were included in the longitudinal analysis.
For AHF patients, correlation coefficients were calculated by Pearson and Spearman tests for normal and non-normal data, respectively. Cox regression analysis was used to establish predictive value of the study for parameters for the study outcome.
Kaplan Meier estimates for the distribution of time from index admission to the primary end-point were computed and log-rank analysis was performed to compare event free survival for patients with values of cFLC, BNP, hsCRP and estimated glomerular filtration rate (eGFR) above and below the median value at admission. Data analysis was carried out using SPSS 18.0 (SPSS Inc, Chicago, IL, USA) and a two-sided p-value of <0.05 was considered statistically significant.
Results
The 3 patient groups (i.e. AHF, SHF, CAD) were comparable for age, gender, blood pressure and body mass index (Table 1 ). Patients with AHF had higher BNP and creatinine levels and lower eGFR vs SHF. As expected, patients with AHF more often received loop diuretics and less beta-blockers than participants from all other groups. Patients with AHF
had increased counts of monocytes and neutrophils and lower haemoglobin concentrations compared to other groups (p<0.001).
Patients with AHF had a highly significant increase in levels of cFLC, cystatin C, hsCRP, interleukin-6, monocytes and neutrophils compared to other groups (p<0.001) ( Table   1 , Figure 1 for cFLC). Also patients with SHF showed higher levels cFLC and cystatin C compared with 'healthy controls' (p<0.05 and p=0.008, respectively). There were no significant differences in hsCRP, interleukin-6 and leukocyte counts between the patients with SHF and control groups free from HF.
In AHF cFLC correlated with cystatin C (Spearman r=0.63, p=0.000001), creatinine (Spearman r=0.47, p=0.002) and inversely with eGFR (Spearman r=-0.39, p=0.01). Cystatin During the 3 month follow up period, there was a significant reduction in BNP concentrations (p=0.017), but no significant change in cFLC or hsCRP levels ( Table 2) . A non-significant trend was observed towards a further increase in cystatin C (p=0.072).
cFLC concentrations were significantly higher in patients reaching the primary endpoint of death or re-hospitalization (72 [86-118] mg/L) compared to those who remained free of events (58 [39-64] mg/L). In a univariate Cox regression analysis, cFLC concentrations were highly significantly associated with the primary end-point and remained associated with the outcome after adjustment for age, gender, BNP, cystatin C levels and LVEF ( Table 3 ). On univariate Cox regression analysis, cFLC concentrations were significantly predictive of the occurrence of the secondary end-point (death alone) and remained associated with the outcome after adjustment for age, gender, BNP and cystatin C levels and LVEF. Levels of hsCRP, interleukin-6 and leukocyte counts were not significantly associated with the primary or secondary outcomes (Table 3) .
To further establish the predictive significance of cFLC in AHF, its values were analysed as quartiles. On univariate Cox regression analysis, quartiles of cFLC were significantly associated with the primary end-point (hazard ratio 2.6 [95% confidence interval For a Kaplan-Meier analysis, patients were dichotomized using the median cFLC value (62 mg/L). Patients with high cFLC (above median levels) had significantly worse outcomes (primary endpoint) compared to those below the median levels (log rank, p=0.00004) ( Figure   2 ). Patients with high cFLC also had a worse outcome for the secondary endpoint (death alone) (log rank, p=0.002) ( Figure 2 ). Kaplan-Meier analyses were performed for BNP, hsCRP and eGFR levels and no significant predictive values were found for these parameters (Supplementary figure 1 ).
Discussion
In this study, we show for the first time a highly significant rise in cFLC in patients with acute decompensated HF. The cFLC levels remained elevated for at least 3 months after HF exacerbation and their high concentrations were strongly associated with poor intermediate term outcomes. Elevated cFLC have been associated with increased all-cause mortality, with circulatory disease being a predominant cause of death; however this is the first report linking cFLC to a specific cardiovascular outcome. 1, 2 Several mechanisms can be responsible for increased cFLC in HF, which could be simplified to their increased production due to stimulation of the adaptive immune system (i.e., B-cell activation and proliferation) [9] [10] [11] and impaired elimination due to dysfunction of the kidneys or reticulo-endothelial system. 12, 13 A combination of all these mechanisms is likely to take place in the setting of AHF. Indeed, patients with AHF typically show some deterioration of renal function and in our study there was a strong association between cFLC levels and parameters of renal impairment, particularly cystatin C levels. 14 removal from the circulation could also be due to diminished pinocytic activity of capillary endothelial cells, which is consistent with endothelial dysfunction that is evident in HF. [15] [16] [17] Although high total lymphocyte counts are generally linked to a better prognosis in HF, sparse clinical data are available on the functionality of B-cell subsets in this condition and their role in immune disarrangement in this disorder. Consequently cFLC may potentially represent a useful prognostic biomarker in HF patients independent of parameters of high intracardiac pressure (i.e. BNP) and inflammation related to innate immunity (i.e., hsCRP).
Indeed, in our study hsCRP correlated with inteleukin-6 concentrations and neutrophil counts, but showed no significant correlation with cFLC, in agreement with previous data. 18 Importantly, cFLC preserved its prognostic significance even after accounting for renal status indicating the cFLC rise is not solely because of renal dysfunction and has incremental prognostic significance in this regard. However, investigation into the exact mechanisms of cFLC upregulation in HF was beyond the scope of this pilot study. Also, it remains unclear whether the prognostic power of cFLC simply reflects the background abnormalities leading to their increase or it could also be attributable to direct detrimental effects of high cFLC concentrations. FLC can cause mast cell degranulation, alter neutrophil chemotaxis and exhibit direct nephrotoxic effects. 19, 20 Indeed, symptomatic improvement in acute HF treated by levosimendan was partly attributable to a reduction in cFLC concentration. 21 This pilot study is relatively small in size and the findings need to be confirmed in larger studies, which will also allow comparison to other biomarkers. Our work also provides only limited insights into mechanisms responsible to cFLC-related abnormalities in HF and does not answer the question of whether high cFLC contribute to HF progression or they are secondary to other processes, which also cause HF deterioration. These questions need to be tested in specifically designed studies. 
